^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)

    i
    Other names: TFE3, Transcription Factor Binding To IGHM Enhancer 3, Class E Basic Helix-Loop-Helix Protein, Transcription Factor E Family, Member A, BHLHe33 , Transcription Factor For Immunoglobulin Heavy-Chain Enhancer 3, Transcription Factor For IgH Enhancer, Transcription Factor E3, RCCP2 , RCCX1, TFEA
    4d
    TFE3 fusion proteins drive TFE3 rearranged renal cell carcinoma progression via PGC-1α-mediated fatty acid oxidation. (PubMed, Front Immunol)
    TFE3 fusion proteins enhance FAO and drive TFE3 rRCC progression via the PGC-1α/PPARα/CPT1A axis. Targeting CPT1A could inhibit tumor cell proliferation, suggesting that this pathway may serve as a potential therapeutic target for TFE3 rRCC.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CPT1A (Carnitine Palmitoyltransferase 1A) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • PPARGC1A (PPARG Coactivator 1 Alpha)
    6d
    Immunophenotypic and Molecular Analysis of a Novel Case of ACTG1::MITF Fusion Clear Cell Tumor With Melanocytic Differentiation. (PubMed, Am J Dermatopathol)
    In addition to detailing specific features of our case, we also discuss those differences that may help distinguish ACTG1::MITF fusions from other clear cell tumors. Considering the significant differences in clinical outcomes between these distinct classes of clear cell tumors, accurate distinction can significantly affect management options.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • SOX10 (SRY-Box 10) • MITF (Melanocyte Inducing Transcription Factor) • ACTG1 (Actin Gamma 1) • CRTC1 (CREB Regulated Transcription Coactivator 1)
    10d
    Jatropadanes A-Q, lathyrane diterpenoids with lysosomal biogenesis potential from Jatropha podagrica Hook. (PubMed, Phytochemistry)
    Jatropodane A (1) forms a 5/5/10/3 ring system, with a new oxygen bridge between C-14 and C-5. Jatropadane B (2) promoted lysosomal biogenesis through the activation of the transcription factors TFEB/TFE3, whereas its inhibitory effects on the proliferation of HepG2 cells were attenuated by the autophagy inhibitor or the knockdown of TFEB and TFE3, suggesting that lysosomal biogenesis and autophagy induced by jatropadane B (2) are favorable programmed death of tumor cell lines.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    11d
    Mammalian lipophagy: process and function. (PubMed, Autophagy)
    In contrast, this review focuses specifically on mammalian lipophagy by synthesizing the latest mechanistic insights into receptor-mediated recognition, transcriptional regulation, and signaling integration. We also outline unresolved questions and conceptual gaps - such as how lipophagy is selectively activated, how it coordinates with lipolysis, and whether distinct receptor codes exist in tissue- and disease-specific contexts - that remain unanswered in the current literature.
    Review • Journal
    |
    SQSTM1 (Sequestosome 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • TFEB (Transcription Factor EB 2) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • TP53INP2 (Tumor Protein P53 Inducible Nuclear Protein 2)
    18d
    Clinicopathological and molecular features of acquired cystic disease-associated renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
    ACD-RCC is a rare renal cell carcinoma that occurs in patients with end-stage renal disease and has unique morphological features. It is often associated with favorable prognosis and alterations in genes related to the MTOR/TSC pathway or chromatin modification.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TSC1 (TSC complex subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MME (Membrane Metalloendopeptidase) • KMT2B (Lysine Methyltransferase 2B) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2)
    |
    TP53 mutation
    21d
    Next-generation liquid biopsies: detecting circulating epigenetic changes to identify translocation renal cell carcinoma. (PubMed, J Clin Invest)
    may enable disease monitoring and subtype classification in other genetically quiet tumors. Epigenomic liquid biopsy is a promising framework to improve diagnostic accuracy and guide personalized management for tRCC.
    Journal • Liquid biopsy
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    21d
    Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. (PubMed, J Clin Invest)
    By defining a TFE3-driven epigenomic signature in tRCC cell lines and detecting it in patient plasma using ChIP-seq, we distinguished tRCC from clear-cell RCC (AUC = 0.86) and samples of individuals without evidence of cancer (AUC = 0.92) at low tumor fractions (<1%). This work establishes a framework for noninvasive epigenomic detection, diagnosis, and monitoring of tRCC, with implications for other mutationally quiet, fusion-driven cancers.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    23d
    Toripalimab Combined with Lenvatinib for Postoperative Adjuvant Therapy in Non-Clear Cell Renal Cell Carcinoma with High Recurrence Risk: An Evaluation of Efficacy and Safety (ChiCTR2500113091)
    P=N/A, N=60, Not yet recruiting, The Third Medical Centre, Chinese PLA General Hospital; The Third Medical Centre, Chinese PLA General Hospital
    New trial
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • FH (Fumarate Hydratase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    25d
    Surgical management of giant Xp11.2 translocation renal cell carcinoma with multivisceral invasion: a case report of en bloc resection and targeted-immunotherapy success. (PubMed, Front Oncol)
    Surveillance MRI at 3 months postoperatively revealed local recurrence, prompting combination therapy with sunitinib (VEGF inhibitor) and sintilimab (anti-PD-1 antibody). Follow-up imaging demonstrated significant regression at 1 month, with no evidence of disease progression at 12-month reassessment.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    |
    sunitinib • Tyvyt (sintilimab)
    27d
    Advances in Renal Cell Carcinoma Diagnosis: a review on Biomarkers. (PubMed, Pathobiology)
    A precise diagnosis integrating histopathology, IHC, and molecular testing is critical for guiding management, identifying hereditary syndromes, and implementing personalized tumor biology-based therapies. With evolving molecular diagnostic and circulating biomarkers, careful clinical integration is needed to optimize outcomes and treatment.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • FH (Fumarate Hydratase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    |
    ALK rearrangement
    1m
    Alternative Lengthening of Telomeres in Malignant PEComas: Correlation with Molecular Features Including ATRX Gene Mutation Status. (PubMed, Mod Pathol)
    Our study provides the first correlation between ALT and genomic features of malignant PEComas, demonstrating that ATRX alterations invariably predict ALT, but that a subset of tumors without mutations in known ALT suppressor genes also activate ALT. These findings confirm that the association between ATRX alterations and ALT observed in other tumor types applies to PEComas and indicate that in a subset of cases, ALT may be activated by ATRX independent mechanisms.
    Journal
    |
    ATRX (ATRX Chromatin Remodeler) • TSC1 (TSC complex subunit 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    1m
    TFE-Altered Renal Cell Carcinoma: A Contemporary Review With Practical Insights and Diagnostic Pearls for Surgical Pathologists. (PubMed, Adv Anat Pathol)
    Given their ability to mimic one another as well as more common RCC subtypes, we present a review here that summarizes relevant morphologic, immunohistochemical, and molecular findings as well as a practical approach to diagnosis. Accurate diagnosis of TFE-altered RCCs is critical to provide patients and treating clinicians with pertinent prognostic information and inform treatment decisions in the event of advanced disease.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4) • TFEB (Transcription Factor EB 2)